IL33 and agammaglobulinemia: Other currently investigated drugs with significantly less evidence in the area of food allergies are dupilumab [238], the anti-IgE antibody ligelizumab (currently in a phase III trial for peanut allergy) [239], agammaglobulinemia TKI acalabrutinib (completed phase II [240]) and etokimab (anti-IL-33 antibody) [241, 242].